Amgen received two approvals from regulators over the Thanksgiving weekend, allowing its deal to acquire a minority stake in a Chinese biotechnology firm to move forward and granting orphan drug status to anemia treatment Nplate. The Thousand Oaks-based pharma giant announced the deal to acquire a 20 percent stake in oncology research firm BeiGene for…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
